DK1749517T3 - Stable pharmaceutical composition of linezolid form IV - Google Patents

Stable pharmaceutical composition of linezolid form IV

Info

Publication number
DK1749517T3
DK1749517T3 DK06250227T DK06250227T DK1749517T3 DK 1749517 T3 DK1749517 T3 DK 1749517T3 DK 06250227 T DK06250227 T DK 06250227T DK 06250227 T DK06250227 T DK 06250227T DK 1749517 T3 DK1749517 T3 DK 1749517T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
linezolid
linezolid form
stable pharmaceutical
patient
Prior art date
Application number
DK06250227T
Other languages
Danish (da)
Inventor
Ruth Tenengauzer
Minutza Leibovici
Ben-Zion Solomon
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36129715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1749517(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK1749517T3 publication Critical patent/DK1749517T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method of formulating linezolid to provide a solid pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II, methods of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV substantially free of linezolid Form II.
DK06250227T 2005-07-20 2006-01-17 Stable pharmaceutical composition of linezolid form IV DK1749517T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70143805P 2005-07-20 2005-07-20

Publications (1)

Publication Number Publication Date
DK1749517T3 true DK1749517T3 (en) 2008-11-03

Family

ID=36129715

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06250227T DK1749517T3 (en) 2005-07-20 2006-01-17 Stable pharmaceutical composition of linezolid form IV

Country Status (15)

Country Link
US (1) US20070020329A1 (en)
EP (1) EP1749517B8 (en)
JP (1) JP2009501794A (en)
CN (1) CN101262853A (en)
AT (1) ATE400257T1 (en)
AU (1) AU2006277017A1 (en)
CA (1) CA2612481A1 (en)
DE (1) DE602006001699D1 (en)
DK (1) DK1749517T3 (en)
ES (1) ES2309920T3 (en)
HK (1) HK1097774A1 (en)
IL (1) IL188176A0 (en)
PL (1) PL1749517T3 (en)
PT (1) PT1749517E (en)
WO (1) WO2007018588A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007102082A1 (en) * 2006-03-09 2007-09-13 Glenmark Pharmaceuticals Limited High oxazolidinone content solid dosage forms
WO2011080570A2 (en) * 2009-12-29 2011-07-07 Micro Labs Limited Extended release pharmaceutical composition comprising linezolid and process for preparing the same
US9132132B2 (en) * 2010-09-02 2015-09-15 Hetero Research Foundation Pharmaceutical compositions of linezolid
CN102885788B (en) * 2011-07-22 2016-06-29 重庆华邦制药有限公司 A kind of Linezolid sheet of stable crystal form and preparation method thereof
WO2013088389A1 (en) * 2011-12-14 2013-06-20 Alembic Pharmaceuticals Limited Linezolid premix
CN103099792B (en) * 2012-12-10 2014-11-26 成都欣捷高新技术开发有限公司 Preparation method of IV crystal linezolid tablets having high drug loading capacity and capable of quickly dissolving
CN103893138B (en) * 2012-12-28 2017-09-29 成都国为生物医药有限公司 A kind of tablet containing linezolid form III
CN104370846B (en) * 2013-08-15 2017-04-12 杭州华东医药集团新药研究院有限公司 Method for preparing linezolid IV crystal form
CN104622831B (en) * 2013-11-06 2018-06-22 江苏豪森药业集团有限公司 A kind of oral tablet and preparation method thereof
CN104173303B (en) * 2014-08-14 2017-01-11 杭州华东医药集团新药研究院有限公司 Linezolid-containing composition and preparation method thereof
CN104586812A (en) * 2014-12-25 2015-05-06 杭州华东医药集团新药研究院有限公司 Composition containing linezolid as well as preparation method thereof
PL3170864T3 (en) * 2015-11-17 2019-04-30 Borealis Ag High flow tpo composition with excellent balance in mechanical properties for automotive interior
CN111675669A (en) * 2020-05-15 2020-09-18 扬子江药业集团北京海燕药业有限公司 Linezolid crystal form, preparation method and pharmaceutical composition thereof
CN118059106B (en) * 2024-04-17 2024-06-28 山东新时代药业有限公司 Linezolid antibacterial preparation and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
AR027261A1 (en) * 2000-02-02 2003-03-19 Upjohn Co LINEZOLID CRYSTAL FORM II
US6444813B2 (en) * 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
EA006772B1 (en) * 2000-03-22 2006-04-28 Фармация Энд Апджон Компани Linezolid-based compressed tablet and use thereof
US6514529B2 (en) * 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
HUE051230T2 (en) * 2003-10-16 2021-03-01 Symed Labs Ltd A crystalline form of linezolid
CA2572054A1 (en) * 2004-06-29 2006-01-12 Teva Pharmaceutical Industries Ltd. Crystalline form iv of linezolid

Also Published As

Publication number Publication date
CA2612481A1 (en) 2007-02-15
ES2309920T3 (en) 2008-12-16
WO2007018588A8 (en) 2008-05-08
CN101262853A (en) 2008-09-10
ATE400257T1 (en) 2008-07-15
AU2006277017A1 (en) 2007-02-15
WO2007018588A1 (en) 2007-02-15
EP1749517B8 (en) 2008-10-22
PT1749517E (en) 2008-09-29
PL1749517T3 (en) 2008-12-31
IL188176A0 (en) 2008-03-20
JP2009501794A (en) 2009-01-22
HK1097774A1 (en) 2007-07-06
DE602006001699D1 (en) 2008-08-21
EP1749517A1 (en) 2007-02-07
EP1749517B1 (en) 2008-07-09
US20070020329A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
DK1749517T3 (en) Stable pharmaceutical composition of linezolid form IV
LTC1781298I2 (en) Pharmaceutical compositions containing benzoxazine for the treatment of respiratory diseases
AR110413A2 (en) COMPOUND 5-CHLORINE-N - ((5S) -2-OXO-3- [4- (3-OXO-4-MORFOLINIL) PHENYL] -1,3-OXAZOLIDIN-5-ILMETIL) -2-THIOFENCARBOXAMIDE
GEP20135803B (en) Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
MX2009008439A (en) Novel inhibitors hepatitis c virus replication.
ATE410424T1 (en) SPIROCYCLIC CYCLOHEXANE DERIVATIVES
DK2023918T3 (en) Cyclosporins for the treatment and prevention of ocular disorders
SE0401971D0 (en) Piperidne derivatives
NO20072094L (en) Hood for drug delivery device
TW200716628A (en) Novel compounds
NO20075111L (en) Pharmaceutical composition
EA201100305A1 (en) TREATMENT OF RESPIRATORY DISEASES
CY1112320T1 (en) TAPENDADOL TITLE
NO20064078L (en) Substituted azetidine compositions, their preparation and use as drugs
GB0514463D0 (en) Use of pinolenic acid
EA201170753A1 (en) NALMEPHENA HYDROCHLORIDE DIHYDRATE
SE0401342D0 (en) Therapeutic compounds
SE0401970D0 (en) Novel compounds
EA201170512A1 (en) COMPOSITION FOR ORAL ADMINISTRATION
CY1108196T1 (en) ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS ADMINISTRATED BY ORAL
DE502007005902D1 (en) -METHYL-19-NOR-20-SPIROX-4-EN-3-ONE), as well as the PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF
RU2007122391A (en) S-MIRTAZAPINE FOR TIDAL TREATMENT
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
DOP2011000082A (en) SALTS OF N- [6- (CIS-2,6-DIMETIL-MORFOLIN-4-IL) -PIRIDIN-3-IL] -2-METHYL-4- (TRIFLUOROMETOXI) - [1,1'-BIFENIL] -3 -CARBOXAMIDE
SE0501903L (en) Boron compounds useful at BNCT